APA (7th ed.) Citation

R, B., EC, P., JT, W., PC, Y., JH, T., TD, H., . . . RD, S. (2020). Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial. JACC. CardioOncology, 2(4), 581. https://doi.org/10.1016/j.jaccao.2020.09.001

Chicago Style (17th ed.) Citation

R, Bolli, et al. "Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial." JACC. CardioOncology 2, no. 4 (2020): 581. https://doi.org/10.1016/j.jaccao.2020.09.001.

MLA (9th ed.) Citation

R, Bolli, et al. "Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial." JACC. CardioOncology, vol. 2, no. 4, 2020, p. 581, https://doi.org/10.1016/j.jaccao.2020.09.001.